SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as ...

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Intellia Therapeutics is a clinical-stage leader focused on CRISPR-based gene editing to treat diseases at their genetic source. The company primarily advances therapies for hereditary angioedema (HAE ...

The recent announcement of novel, viable viruses created by artificial intelligence (AI) was celebrated as a major advance in the fight against antibiotic resistance. But it also raised urgent ...